NCT00621270 - Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety | Biotech Hunter

Enrollment

115

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

Major Depressive DisorderAnxiety

Interventions

DRUG

BCI-540

BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo

Trial Locations (16)

T6L 5X8

Grey Nuns Hospital, Clinical Research, Edmonton

V1Y 2H4

Okanagan Clinical Trials, Kelowna

V2A 4M4

Dr. Alexander McIntyre, Inc, Penticton

V6T 2A1

University of British Columbia Mood Disorders Centre, Vancouver

V6Z 2L4

Dr. D. McIntosh & Dr. K. Kjernisted Clinical Research Inc., Vancouver

R6W 1T4

Eden Mental Health Centre, Winkler

E1V 3G5

Sanjay Siddhartha, MD, Miramichi

B3H 2E2

Queen Elizabeth II Health Sciences Centre, Halifax

B1S 2E8

Autar K. Munshi, MD, Sydney

N7M 5L9

Robert Fairbairn, MD, Chatham

K7L 4X3

Providence Care Mental Health Services, Kingston

N6A 5R9

Robert G. Luton, MD, London

L5M 4N4

Anxiety and Mood Disorder Center, Mississauga

K1G 4G3

Ottawa Psychopharmacology Clinic, Ottawa

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5G 2C4

University Health Network, Dept. of Psychiatry, Toronto